Literature DB >> 25329751

Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.

C Rosin1, L Elzi, C Thurnheer, J Fehr, M Cavassini, A Calmy, P Schmid, E Bernasconi, M Battegay.   

Abstract

OBJECTIVES: Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a subject of controversy. We aimed to compare treatment responses between genders in a setting of equal access to cART over a 14-year period.
METHODS: Analyses included treatment-naïve participants in the Swiss HIV Cohort Study starting cART between 1998 and 2011 and were restricted to patients infected by heterosexual contacts or injecting drug use, excluding men who have sex with men.
RESULTS: A total of 3925 patients (1984 men and 1941 women) were included in the analysis. Women were younger and had higher CD4 cell counts and lower HIV RNA at baseline than men. Women were less likely to achieve virological suppression < 50 HIV-1 RNA copies/mL at 1 year (75.2% versus 78.1% of men; P = 0.029) and at 2 years (77.5% versus 81.1%, respectively; P = 0.008), whereas no difference between sexes was observed at 5 years (81.3% versus 80.5%, respectively; P = 0.635). The probability of virological suppression increased in both genders over time (test for trend, P < 0.001). The median increase in CD4 cell count at 1, 2 and 5 years was generally higher in women during the whole study period, but it gradually improved over time in both sexes (P < 0.001). Women also were more likely to switch or stop treatment during the first year of cART, and stops were only partly driven by pregnancy. In multivariate analysis, after adjustment for sociodemographic factors, HIV-related factors, cART and calendar period, female gender was no longer associated with lower odds of virological suppression.
CONCLUSIONS: Gender inequalities in the response to cART are mainly explained by the different prevalence of socioeconomic characteristics in women compared with men.
© 2014 British HIV Association.

Entities:  

Keywords:  HIV/AIDS; antiretroviral therapy; gender differences; outcome; women

Mesh:

Year:  2014        PMID: 25329751     DOI: 10.1111/hiv.12203

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  10 in total

1.  Age Differences by Sex in Antiretroviral-Naïve Participants: Pooled Analysis from Randomized Clinical Trials.

Authors:  LaRee A Tracy; Kimberly Struble; Cynthia Firnhaber; Laura Smeaton; Jordan E Lake; Tanvir Bell; Guoxing Gregg Soon; Jin Yan; Kathryn Schnippel; Susan E Cohn
Journal:  J Assoc Nurses AIDS Care       Date:  2018-02-02       Impact factor: 1.354

2.  What's new for antiretroviral treatment in women with HIV.

Authors:  Nisha Andany; Sharon L Walmsley
Journal:  J Virus Erad       Date:  2016-04-01

3.  Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses.

Authors:  Lisa S Burch; Colette J Smith; Jane Anderson; Lorraine Sherr; Alison J Rodger; Rebecca O'Connell; Anna-Maria Geretti; Richard Gilson; Martin Fisher; Jonathan Elford; Martin Jones; Simon Collins; Yusef Azad; Andrew N Phillips; Andrew Speakman; Margaret A Johnson; Fiona C Lampe
Journal:  Lancet Public Health       Date:  2016-11

Review 4.  HIV Drug Resistance in Children and Adolescents: Always a Challenge?

Authors:  Wei Li A Koay; Judith Kose-Otieno; Natella Rakhmanina
Journal:  Curr Epidemiol Rep       Date:  2021-03-18

5.  Sex differences and adverse events of antiretrovirals in people living with HIV/AIDS: a systematic review and meta-analysis protocol.

Authors:  Jardel Corrêa de Oliveira; Maíra Ramos Alves; Luis Phillipe Nagem Lopes; Rodrigo Suguimoto Iwami; Fabiane Raquel Motter; Cristiane de Cássia Bergamaschi; Marcus Tolentino Silva; Alexander Itria; Diogo Luis Scalco; Donavan de Souza Lucio; Lauren Giustti Mazzei; Rodrigo D'Agostini Derech; Tiago Veiga Pereira; Jorge Otávio Maia Barreto; Luciane Cruz Lopes
Journal:  BMJ Open       Date:  2022-02-24       Impact factor: 2.692

6.  Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV.

Authors:  Valentina Delle Donne; Valentina Massaroni; Nicoletta Ciccarelli; Francesca Lombardi; Alberto Borghetti; Arturo Ciccullo; Alex Dusina; Damiano Farinacci; Ganmaria Baldin; Elena Visconti; Enrica Tamburrini; Simona Di Giambenedetto
Journal:  J Neurovirol       Date:  2022-06-19       Impact factor: 3.739

7.  Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014.

Authors:  Junko Tanuma; Kyu Ha Lee; Sebastien Haneuse; Shoko Matsumoto; Dung Thi Nguyen; Dung Thi Hoai Nguyen; Cuong Duy Do; Thuy Thanh Pham; Kinh Van Nguyen; Shinichi Oka
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

8.  High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa.

Authors:  Kogieleum Naidoo; Razia Hassan-Moosa; Nonhlanhla Yende-Zuma; Dhineshree Govender; Nesri Padayatchi; Halima Dawood; Rochelle Nicola Adams; Aveshen Govender; Tilagavathy Chinappa; Salim Abdool-Karim; Quarraisha Abdool-Karim
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

9.  Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO" Cohort.

Authors:  Emanuele Focà; Paola Magro; Giovanni Guaraldi; Agostino Riva; Anna Maria Cattelan; Giuseppe Vittorio De Socio; Cecilia Costa; Stefania Piconi; Benedetto Maurizio Celesia; Silvia Nozza; Giancarlo Orofino; Antonella Castagna; Giovanni Di Perri; Francesco Castelli; Andrea Calcagno
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

10.  All-cause hospitalization according to demographic group in people living with HIV in the current antiretroviral therapy era.

Authors:  Sophia M Rein; Fiona C Lampe; Margaret A Johnson; Sanjay Bhagani; Robert F Miller; Clinton Chaloner; Andrew N Phillips; Fiona M Burns; Colette J Smith
Journal:  AIDS       Date:  2021-02-02       Impact factor: 4.632

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.